| Clinical Relapse (n = 41) | |||||
---|---|---|---|---|---|---|
Univariable | Multivariablea | |||||
HR | 95% CI | P | HR | 95% CI | P | |
End of treatment | ||||||
 Age | 1.069 | 1.025–1.114 | 0.002 | 1.062 | 1.016–1.110 | 0.007 |
 Age > 35 y | 2.647 | 1.324–5.291 | 0.006 |  |  |  |
 Sex | 1.44 | 0.662–3.133 | 0.358 |  |  |  |
 First-line NA therapy b | 1.233 | 0.667–2.281 | 0.504 |  |  |  |
 Consolidation duration | 0.996 | 0.980–1.011 | 0.596 |  |  |  |
 Consolidation duration 3 > y | 0.777 | 0.401–1.508 | 0.456 |  |  |  |
 ALT × ULN | 0.861 | 0.331–2.241 | 0.759 |  |  |  |
 HBsAg log10 IU/ml | 1.1725 | 1.177–2.529 | 0.005 | 2.086 | 1.286–3.385 | 0.003 |
 HBsAg >200IUmL (vs ≤ 200IUmL) | 3.697 | 1.447–9.444 | 0.006 |  |  |  |
 HBV DNA level elevation log10 IU/ml | 1.000 | 1.000–1.000 | 0.030 | 1.000 | 1.000–1.000 | 0.045 |
 HBV DNA level elevation > 20000 IU/ml (vs ≤ 20000 IU/ml) | 2.531 | 1.179–5.435 | 0.017 |  |  |  |
 sST2 log10 pg/mL | 2.816 | 0.731–10.845 | 0.132 |  |  |  |
 sST2 > 3.7 log10 pg/mL(vs ≤ 3.7 log10 pg/mL) | 1.718 | 0.841–3.508 | 0.137 |  |  |  |
 12 W sST2 log10 pg/mL | 4.655 | 2.345–9.243 | < 0.001 | 4.403 | 2.169–8.937 | < 0.001 |
Start of treatment | ||||||
 HBeAg | 0.726 | 0.384–1.375 | 0.326 |  |  |  |
 ALT × ULN | 0.986 | 0.935–1.019 | 0.403 |  |  |  |
 HBV DNA log10 IU/ml | 0.745 | 0.792–1.385 | 0.745 |  |  |  |